Alamar Biosciences, Inc.
ALMR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.75B
Close$
$2.35
90.7% downside
Current Fair Value
90.7% downsideOvervalued by 90.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.75 Billion |
|---|---|
| Enterprise Value | $1.67 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.45 |
| Beta | -6.18 |
| Outstanding Shares | 58,665,055 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -47.68 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 5.06 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
$25.86 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$30.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 35.54%▲ 35.54% |
|---|---|
| Total Invested | $667.43M |
| Investors Holding | 88▲ 88.00% |
ESG Score
No data
About Alamar Biosciences, Inc.
222 employees
CEO: Yuling Luo Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated ...